SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-24-004479
Filing Date
2024-08-06
Accepted
2024-08-06 16:01:13
Documents
16
Period of Report
2024-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_080624.htm   iXBRL 8-K 15680
2 PRESS RELEASE exh_991.htm EX-99.1 63363
7 GRAPHIC chart.jpg GRAPHIC 203957
  Complete submission text file 0001171843-24-004479.txt   543958

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3003
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25598
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
18 EXTRACTED XBRL INSTANCE DOCUMENT f8k_080624_htm.xml XML 3327
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 241178963
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)